{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:14Z","timestamp":1788335054599,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Mater Private Hospital in Dublin Ireland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To compare flecainide and dronedarone for sinus rhythm (SR) maintenance following electrocardioversion of persistent atrial fibrillation (AF), in patients with minimal or no structural heart disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A systematic search of publications using EMBASE, CENTRAL, CINAHL, and MEDLINE (1989\u20132019), identified a total of 595 articles. No limitations were applied. Nine articles met the inclusion criteria [five randomized controlled trials (RCTs) and four cohort studies], encompassing 1349 persistent AF candidates. Two retrospective studies compared flecainide with dronedarone, indicating a 6% reduced risk of AF recurrence with flecainide; however, results were not statistically significant [risk ratio (RR) 0.94, 95% confidence interval (CI) 0.71\u20131.24; P\u2009=\u20090.66]. One RCT compared dronedarone to placebo, demonstrating a 28% reduced risk of AF recurrence at 6\u2009months (RR 0.72, 95% CI 0.58\u20130.90; P\u2009=\u20090.004). Two RCTs compare flecainide to placebo, when a 16% decreased risk of AF recurrence at 6\u201312\u2009months was indicated; however, these results were not statistically significant (RR 0.84, 95% CI 0.66\u20131.07; P\u2009=\u20090.16). Within a 6- to 12-month follow-up period, a combined recurrence rate of AF was examined, in which flecainide and dronedarone maintained SR in 50% and 42%, respectively. Four articles satisfied quality appraisal, one of which focused on flecainide data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Dronedarone and flecainide displayed similar efficacy in maintaining SR in patients following electrocardioversion for persistent AF. The SR maintenance was numerically but not statistically significant in the flecainide group. Side effects uncovered similar pro-arrhythmic activity. However, in light of the deficiency of volume and quality of available evidence, the writer acknowledges the requirement for future research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa018","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:25:10Z","timestamp":1583497510000},"page":"363-372","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-8218","authenticated-orcid":false,"given":"Hannah","family":"Wilson","sequence":"first","affiliation":[{"name":"School of Nursing and Midwifery, Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, 123 St Stephen's Green, Dublin D02 YN77, Ireland"},{"name":"Mater Private Hospital, Eccles St, Northside, Dublin D07 WKW8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-2605","authenticated-orcid":false,"given":"Declan","family":"Patton","sequence":"additional","affiliation":[{"name":"School of Nursing and Midwifery, Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, 123 St Stephen's Green, Dublin D02 YN77, Ireland"},{"name":"Faculty of Science, Medicine and Health, University of Wollongong, Northfields Ave, Wollongong, NSW 2522, Australia"},{"name":"Fakeeh College of Health Sciences, Abdul Wahab Naib Al Haram, Al-Hamra'a, Jeddah 23323, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-9718","authenticated-orcid":false,"given":"Zena","family":"Moore","sequence":"additional","affiliation":[{"name":"School of Nursing and Midwifery, Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, 123 St Stephen's Green, Dublin D02 YN77, Ireland"},{"name":"Fakeeh College of Health Sciences, Abdul Wahab Naib Al Haram, Al-Hamra'a, Jeddah 23323, Saudi Arabia"},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University, 27 Rainforest Walk, Wellington Rd, Clayton VIC 3800, Melbourne, Australia"},{"name":"Department of Public Health, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 3K3, Gent 9000, Belgium"},{"name":"Lida Institute, 1788 Cheting Hwy, Songjiang District, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-0975","authenticated-orcid":false,"given":"Tom","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"School of Nursing and Midwifery, Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, 123 St Stephen's Green, Dublin D02 YN77, Ireland"},{"name":"Fakeeh College of Health Sciences, Abdul Wahab Naib Al Haram, Al-Hamra'a, Jeddah 23323, Saudi Arabia"},{"name":"Lida Institute, 1788 Cheting Hwy, Songjiang District, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-8545","authenticated-orcid":false,"given":"Linda","family":"Nugent","sequence":"additional","affiliation":[{"name":"School of Nursing and Midwifery, Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, 123 St Stephen's Green, Dublin D02 YN77, Ireland"},{"name":"Fakeeh College of Health Sciences, Abdul Wahab Naib Al Haram, Al-Hamra'a, Jeddah 23323, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"2021092108334043000_pvaa018-B1","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham heart study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"2021092108334043000_pvaa018-B2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11936-007-0057-7","article-title":"When, how, and why should sinus rhythm be restored in patients with persistent atrial fibrillation?","volume":"9","author":"Stephenson","year":"2007","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2021092108334043000_pvaa018-B3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2021092108334043000_pvaa018-B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2015.07.020","article-title":"Restoration of sinus rhythm results in early and late improvements in the functional reserve of the heart following direct current cardioversion of persistent AF: FRESH-AF","volume":"1","author":"Gilbert","year":"2015","journal-title":"Int J Cardiol"},{"key":"2021092108334043000_pvaa018-B5","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"2021092108334043000_pvaa018-B6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/europace\/eun048","article-title":"Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation","volume":"10","author":"Ringborg","year":"2008","journal-title":"EP Europace"},{"key":"2021092108334043000_pvaa018-B7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.108.824847","article-title":"Pharmacological and electrical conversion of atrial fibrillation to sinus rhythm is worth the effort","volume":"120","author":"Anter","year":"2009","journal-title":"Circulation"},{"key":"2021092108334043000_pvaa018-B8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/europace\/eul107","article-title":"The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm","volume":"8","author":"Van Gelder","year":"2006","journal-title":"Europace"},{"key":"2021092108334043000_pvaa018-B9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological mechanisms of atrial fibrillation: a translational appraisal","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol Rev"},{"key":"2021092108334043000_pvaa018-B10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.hfc.2015.08.017","article-title":"Antiarrhythmic drug therapy for atrial fibrillation","volume":"12","author":"Sardar","year":"2016","journal-title":"Heart Fail Clin"},{"key":"2021092108334043000_pvaa018-B11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/01.CIR.101.10.1145","article-title":"Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans","volume":"101","author":"Hobbs","year":"2000","journal-title":"Circulation"},{"key":"2021092108334043000_pvaa018-B12","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2021092108334043000_pvaa018-B13","volume-title":"Symposium on Cardiac Arrhythmias","author":"Vaughan Williams","year":"1970"},{"key":"2021092108334043000_pvaa018-B14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00002512-200219110-00002","article-title":"Atrial fibrillation in the elderly: facts and management","volume":"19","author":"Chatap","year":"2002","journal-title":"Drugs Aging"},{"key":"2021092108334043000_pvaa018-B15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/13543784.13.4.415","article-title":"Dronedarone: an amiodarone analogue","volume":"13","author":"Doggrell","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"2021092108334043000_pvaa018-B16","first-page":"1274","article-title":"Clinical effectiveness of antiarrhythmic treatment after electrical cardioversion in patients without structural heart disease","volume":"61","author":"Alegret","year":"2008","journal-title":"Rev Esp Cardiol"},{"key":"2021092108334043000_pvaa018-B17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jacc.2009.04.085","article-title":"Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation","volume":"54","author":"Piccini","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2021092108334043000_pvaa018-B18","first-page":"1","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"5","author":"Lafuente-Lafuente","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2021092108334043000_pvaa018-B19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2011.594808","article-title":"Dronedarone: an overview","volume":"44","author":"Kozlowski","year":"2012","journal-title":"Ann Med"},{"key":"2021092108334043000_pvaa018-B20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11936-013-0246-5","article-title":"Appropriate and inappropriate use of dronedarone in 2013","volume":"15","author":"Naccarelli","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2021092108334043000_pvaa018-B21","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1517\/17425255.2014.974551","article-title":"Pharmacokinetic and pharmacodynamic profile of dronedarone, a new antiarrhythmic agent for the treatment of atrial fibrillation","volume":"10","author":"Rosa","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2021092108334043000_pvaa018-B22","year":"2014"},{"key":"2021092108334043000_pvaa018-B23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.NAJ.0000465028.05223.39","article-title":"Atrial fibrillation: updated management guidelines and nursing implications","volume":"115","author":"Cutugno","year":"2015","journal-title":"Am J Nurs"},{"key":"2021092108334043000_pvaa018-B24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v7.i2.76","article-title":"Flecainide: current status and perspectives in arrhythmia management","volume":"7","author":"Andrikopoulos","year":"2015","journal-title":"World J Cardiol"},{"key":"2021092108334043000_pvaa018-B25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annemergmed.2008.12.012","article-title":"Rhythm control with electrocardioversion for atrial fibrillation and flutter","volume":"54","author":"Stead","year":"2009","journal-title":"Ann Emerg Med"},{"key":"2021092108334043000_pvaa018-B26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euq450","article-title":"Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation","volume":"13","author":"Freemantle","year":"2011","journal-title":"Europace"},{"key":"2021092108334043000_pvaa018-B27","first-page":"CD005049","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation (review)","volume":"3","author":"Lafuente-Lafuente","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021092108334043000_pvaa018-B28","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLos Med"},{"key":"2021092108334043000_pvaa018-B29","year":"2014"},{"key":"2021092108334043000_pvaa018-B30","first-page":"387","article-title":"A critical appraisal tool for library and information research","volume":"24","author":"Glynn","year":"2006","journal-title":"Emerald Insight"},{"key":"2021092108334043000_pvaa018-B31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0002-9149(89)90574-2","article-title":"Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter","volume":"64","author":"Van Gelder","year":"1989","journal-title":"Am J Cardiol"},{"key":"2021092108334043000_pvaa018-B32","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0195-668X(03)00321-X","article-title":"Dronedarone for prevention of atrial fibrillation: a dose-ranging study","volume":"24","author":"Touboul","year":"2003","journal-title":"Eur Heart J"},{"key":"2021092108334043000_pvaa018-B33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1540-8167.2010.01764.x","article-title":"A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study","volume":"21","author":"Le Heuzey","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2021092108334043000_pvaa018-B34","first-page":"158","article-title":"Adjunctive pharmacotherapy for elective direct current cardioversion in patients with atrial fibrillation","volume":"3","author":"Hirt","year":"2012","journal-title":"Cardiol Res"},{"key":"2021092108334043000_pvaa018-B35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(12)60570-4","article-title":"Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial","volume":"380","author":"Kirchhof","year":"2012","journal-title":"Lancet"},{"key":"2021092108334043000_pvaa018-B36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.clinthera.2014.07.013","article-title":"Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion","volume":"36","author":"Chun","year":"2014","journal-title":"Clin Ther"},{"key":"2021092108334043000_pvaa018-B37","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.ijcard.2012.06.056","article-title":"Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study)","volume":"167","author":"Said","year":"2013","journal-title":"Int J Cardiol"},{"key":"2021092108334043000_pvaa018-B38","doi-asserted-by":"crossref","first-page":"e0197352","DOI":"10.1371\/journal.pone.0197352","article-title":"Which antiarrhythmic drug to choose after electrical cardioversion: a study on non-valvular atrial fibrillation patients","volume":"13","author":"Gwag","year":"2018","journal-title":"PLoS One"},{"key":"2021092108334043000_pvaa018-B39","first-page":"204","article-title":"Comparison of the efficacy and safety of dronedarone and flecainide as maintenance antiarrhythmic therapy for sinus rhythm in atrial fibrillation","volume":"88","author":"Soriano","year":"2018","journal-title":"Arch Cardiol Mex"},{"key":"2021092108334043000_pvaa018-B40"},{"key":"2021092108334043000_pvaa018-B41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.acvd.2011.11.005","article-title":"Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials","volume":"105","author":"Caldeira","year":"2012","journal-title":"Arch Cardiovasc Dis"},{"key":"2021092108334043000_pvaa018-B42","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","article-title":"Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses","volume":"58","author":"Saksena","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2021092108334043000_pvaa018-B43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/eurheartj\/eht457","article-title":"Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study)","volume":"35","author":"Mont","year":"2014","journal-title":"Eur Heart J"},{"key":"2021092108334043000_pvaa018-B44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0008-6363(00)00100-0","article-title":"Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: relation with recurrence","volume":"47","author":"Manios","year":"2000","journal-title":"Cardiovasc Res"},{"key":"2021092108334043000_pvaa018-B45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-5273(01)00522-8","article-title":"Electrical cardioversion for atrial fibrillation: outcomes in \u2018real-life\u2019 clinical practice","volume":"81","author":"Berry","year":"2001","journal-title":"Int J Cardiol"},{"key":"2021092108334043000_pvaa018-B46","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","article-title":"Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2021092108334043000_pvaa018-B47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA Randomized Clinical Trial","volume":"321","author":"Packer","year":"2019","journal-title":"JAMA"},{"key":"2021092108334043000_pvaa018-B48","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ahj.2013.05.015","article-title":"Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial","volume":"166","author":"Kirchhof","year":"2013","journal-title":"AM Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa018\/33150211\/pvaa018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/5\/363\/40418873\/pvaa018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/5\/363\/40418873\/pvaa018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:36:31Z","timestamp":1632213391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/5\/363\/5802468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3,10]]},"published-print":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa018","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2020,3,10]]}}}